A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Clinical trial NCT04791319 · TERMINATED

Trial details

NCT number: NCT04791319
Sponsor: Janssen Research & Development, LLC
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Dermatitis, Atopic

Start date: 2021-05-03
Primary completion: 2022-02-02
Enrollment: 199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.